Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Isocarboxazid chemical structure
| CAS number |
| ATC code |
| PubChem |
| DrugBank |
|Pregnancy category||C (USA)|
|Routes of administration||Oral|
In the United States, isocarboxazid is approved for the treatment of depression.
In the United Kingdom, isocarboxazid is licensed for the treatment of depression unresponsive to selective serotonin reuptake inhibitors (SSRIs).
A randomized controlled trial published in December of 1988 found that isocarboxazid significantly reduced bingeing and purging in bulimia nervosa, regardless of the presence or absence of depression or personality disorder.
MARPLAN® by Hoffmann-La Roche, starting in 1959 and discontinuing in 1994. After much patient and physician outcry, they resumed manufacturing just enough Marplan® to distribute on an as-needed basis. In October of 1998, Hoffmann-La Roche and Oxford Pharmaceutical Services Inc. announced that Oxford, "is acquiring ownership of the NDA for the antidepressant product Marplan® (isocarboxazid) from Roche."
The maximum daily dose of isocarboxazid is 60mg.
Isocarboxazid is availably generically in the United Kingdom in the form of 10mg tablets. However, it is considered 'less suitable for prescribing' by the British National Formulary (BNF).
- drugs.com Isocarboxazid Drug Information
- Monoamine-oxidase inhibitors (Group PIM G025) IPCS INTOX Databank
- PubChem Substance Summary: Isocarboxazid National Center for Biotechnology Information.
- ^ Kennedy SH, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C, Garfinkel PE. "A trial of isocarboxazid in the treatment of bulimia nervosa." Journal of Clinical Psychopharmacology. 1988 Dec;8(6):391-6. PMID 3069879
- ^ Marplan Press Release Oxford Pharmaceutical Services.
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|